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Hypoxia is a characteristic of many solid tumors and an adverse prognostic factor for 
treatment outcome. Hypoxia increases the expression of carbonic anhydrase IX (CAIX), 
an enzyme that is predominantly found on tumor cells and is involved in maintaining 
the cellular pH balance. Many clinical studies investigated the prognostic value of CAIX 
expression, but most have been inconclusive, partly due to small numbers of patients 
included. The present meta-analysis was therefore performed utilizing the results of all 
clinical studies to determine the prognostic value of CAIX expression in solid tumors. 
Renal cell carcinoma was excluded from this meta-analysis due to an alternative mech-
anism of upregulation. 958 papers were identified from a literature search performed in 
PubMed and Embase. These papers were independently evaluated by two reviewers 
and 147 studies were included in the analysis. The meta-analysis revealed strong 
significant associations between CAIX expression and all endpoints: overall survival 
[hazard ratio (HR) =  1.76, 95% confidence interval (95%CI) 1.58–1.98], disease-free 
survival (HR  =  1.87, 95%CI 1.62–2.16), locoregional control (HR  =  1.54, 95%CI 
1.22–1.93), disease-specific survival (HR =  1.78, 95%CI 1.41–2.25), metastasis-free 
survival (HR  =  1.82, 95%CI 1.33–2.50), and progression-free survival (HR  =  1.58, 
95%CI 1.27–1.96). Subgroup analyses revealed similar associations in the majority of 
tumor sites and types. In conclusion, these results show that patients having tumors 
with high CAIX expression have higher risk of locoregional failure, disease progression, 
and higher risk to develop metastases, independent of tumor type or site. The results 
of this meta-analysis further support the development of a clinical test to determine 
patient prognosis based on CAIX expression and may have important implications for 
the development of new treatment strategies.
Keywords: cancer, carbonic anhydrase iX, hypoxia, meta-analysis, prognosis
Abbreviations: 95%CI, 95% confidence interval; CAIX, carbonic anhydrase IX; DFS, disease-free survival; DSS, disease-
specific survival; HIF, hypoxia-inducible factor; HR, hazard ratio; LC, locoregional control; MFS, metastasis-free survival; 
NOS, Newcastle–Ottawa scale; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma; TMAs, tissue 
microarrays; VHL, Von Hippel–Lindau protein.
FiGURe 1 | Flowchart of selecting articles describing the association 
between tumoral CAiX expression and prognosis.
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iNTRODUCTiON
Hypoxia is a characteristic of many different types of solid tumors 
and is caused by an inadequate vascular supply. Hypoxic areas 
are characterized by low oxygen concentrations, limited nutrient 
supply, and an acidic extracellular environment. Hypoxia is an 
independent prognostic factor of poor outcome in patients (1) 
and decreases the efficacy of standard treatment modalities, such 
as surgery, chemotherapy, and radiotherapy (2–4). Many strate-
gies are therefore being investigated to measure tumor hypoxia 
to predict treatment outcome and to overcome or target tumor 
hypoxia with newly designed treatments (5–8).
Tumor cells have adopted several mechanisms to survive the 
hostile conditions during hypoxia, of which one is the hypoxia-
inducible factor (HIF) pathway (9, 10). Upon hypoxic conditions, 
the expression of the dimeric zinc-containing glycoprotein 
carbonic anhydrase IX (CAIX) is enhanced as a consequence 
of HIF stabilization (11, 12). CAIX is important in maintaining 
the cellular pH regulation and is located on the cell membrane 
where it hydrolyzes carbon dioxide, produced as a waste product 
during glycolysis, to bicarbonate and a proton. The bicarbonate 
is transported intracellularly by different proteins (e.g., anion 
exchangers), thereby slightly increasing the intracellular pH to 
promote tumor cell proliferation. The protons in turn add to an 
acidic extracellular environment causing extracellular matrix 
degradation favoring invasion, migration, and subsequent 
metastasis formation (12). Hypoxia-induced CAIX expression, 
tumor-specific expression of CAIX, and its important role in 
maintaining the pH balance make CAIX a promising endogenous 
marker of tumor hypoxia and an attractive target for anti-cancer 
therapies with newly designed inhibitors (6, 11, 12).
Many clinical studies investigated the prognostic value of 
CAIX, and a recent meta-analysis of renal cell carcinoma (RCC) 
concluded that high CAIX expression was associated with a better 
overall survival (OS) (13). By contrast, a meta-analysis in head 
and neck cancer patients showed high CAIX expression was 
associated with a decrease in both OS and disease-free survival 
(DFS) (14). This discrepancy can be explained by the fact that 
RCCs are often characterized by an inactive mutant version of 
the Von Hippel–Lindau (VHL) protein preventing proteasomal 
degradation of CAIX upon normoxia and making its expression 
therefore independent of hypoxia (15, 16). To the best of our 
knowledge, a comprehensive meta-analysis of the association 
between CAIX expression and treatment outcome in other tumor 
types has not been performed. The aim of this meta-analysis of 
published clinical studies is therefore to elucidate the prognostic 
value of CAIX expression in all solid tumor types besides RCC. In 
addition, current analysis has included sensitivity and subgroup 
analysis to be able to determine if the prognostic value of CAIX 
expression varies in patients with different tumor types.
MeTHODS
Literature Search
The research question of this meta-analysis was defined as fol-
lows: “what is the prognostic value of tumoral CAIX expression 
in patients with solid tumors?” From this research question, three 
distinctive keywords were identified, i.e., prognosis, CAIX, and 
tumor. Different formulations and truncations of the keywords 
were tested as free text searches to see if appropriate papers 
could be identified. The search algorithm was applied as a free 
text search and consisted of the combined mention of all three 
keywords, in any of the formulations or truncations (Data sheet 
1 in Supplementary Material). The search for literature was 
performed on the 31st of August 2015 in both the PubMed and 
Embase databases. A total of 958 papers were identified from 
both databases (Figure 1).
exclusion Criteria
From the total number of papers, 134 reviews, conference abstracts, 
commentaries, meta-analyses, editorials, or book chapters were 
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excluded, as were 26 duplicates or non-English papers. From the 
remaining articles, 132 papers about RCC were excluded, since 
upregulation of CAIX in RCC is biologically different from other 
solid tumor types (15, 16). Furthermore, from our experience, 
we know that papers that describe solely the development and 
synthesis of CAIX inhibitors do not include patient data, and 53 
papers were therefore also excluded. The total number of papers 
for further screening was thereby reduced to 613 (Figure 1).
Screening of Papers
Two researchers (SK and AY) screened the remaining papers 
independently. The first round of screening was based on the 
title and abstract, whereas the second round consisted of a 
detailed evaluation of the full-text. Papers were evaluated based 
on the predetermined inclusion criteria. First, only solid primary 
tumors of various types were included, thereby automatically 
excluding hematological cancer. Second, only immunohis-
tochemical detection of CAIX was included, because mRNA 
upregulation of CA9 does not fully correlate with an increase 
in functional protein expression, possibly due to posttranscrip-
tional processing and/or differences in stability (17–19). Third, 
all endpoints were included (see below) with a minimal median 
follow-up of 1 year. Fourth, all treatment modalities along with 
experimental treatments were included. Finally, we included 
every human patient population without making distinction 
based on tumor grades or stages. Discrepancies between the 
included papers by both reviewers were discussed and consen-
sus was reached on all. An additional 14 papers were excluded 
because their patient populations were similar or overlapping 
with other papers. Among these repetitive studies, the paper that 
was included contained the most detailed information about the 
patient population. A total of 144 papers were included in the 
meta-analysis (Figure 1).
Data extraction
Several different parameters, if reported, were extracted from 
each paper, i.e., the number and origin of patients, number of 
events, treatment modalities, tumor site, tumor stage, tumor 
type, group dichotomization, antibody supplier, expression pat-
tern, cellular localization, and endpoints. The univariate hazard 
ratio (HR) was extracted to assess prognostic value of CAIX 
expression. When the univariate HR with corresponding 95% 
confidence interval (95%CI) was not reported, the method from 
Tierney et al. was used to estimate the HR (20). Multivariate HR 
was only included in the meta-analysis when the univariate HR 
was not reported or could not be estimated. When insufficient 
data were reported for estimating HR, the authors were contacted 
to obtain additional data.
Quality Assessment
The methodological quality of the included papers was evaluated 
with an adjusted version of the Newcastle–Ottawa scale (NOS) 
to better suit the study design of the included papers (Data sheet 
2 in Supplementary Material). The method of scoring based 
on awarding stars in different categories remained, however, 
identical. The NOS was commended in the 2011 version of the 
Cochrane Collaboration handbook and is an easy method to 
evaluate the methodological quality of cohort studies (available 
at http://www.ohri.ca/programs/clinical_epidemiology/oxford.
asp) (21).
Statistical Analysis and Sensitivity 
Analysis
Distribution and frequencies of the extracted data parameters 
were analyzed using SPSS (version 22). Meta-analysis was per-
formed using R statistical software with the Metafor Library 
(version 1.9-8) (22). Fixed-effect modeling was performed when 
no statistical significant heterogeneity between studies was 
observed. When the heterogeneity between studies was statisti-
cally significant, random-effects modeling was applied based on 
the DerSimonian and Laird method (23). The assigned weight of 
each study in the analysis was based on its inverse variance. The 
following endpoints have been addressed: OS, DFS, locoregional 
control (LC), disease-specific survival (DSS), metastasis-free 
survival (MFS), and progression-free survival (PFS). Sensitivity 
analysis was performed by analyzing subgroups of studies 
separately, e.g., per tumor organ site. Funnel plots were created 
to visualize possible publication bias or heterogeneity between 
studies. Asymmetric funnel plots and studies outside the funnel 
plot suggest heterogeneity between them and/or publication bias 
(21). p-Values <0.05 were considered as statistically significant.
ReSULTS
This meta-analysis encompassed a total number of 24,523 
patients across 147 independent studies. Many studies included 
only a small number of patients (median per study 93, range 
15–3630) with a median follow-up time between 12.6  months 
and 13.9 years and are often inconclusive, which underlines the 
need for a meta-analysis. All papers were published between 2001 
and 2015 of which approximately 50% were published after 2010. 
The majority of the included studies treated patients with surgery 
alone (36.7%) or in combination with either chemotherapy (8.8%) 
or standard radiotherapy (8.8%), or the combination of all three 
modalities (23.1%). Single radiotherapy treatment or combined 
with chemotherapy was reported in 5.4 and 6.1% of the papers, 
respectively. In 4.8% of the studies, a form of experimental treat-
ment was administered, including experimental radiotherapy 
(24–28), hormonal treatment (29), and VEGF-targeted therapy 
(30). Most of the studies reported on head and neck cancer 
patients (21.8%) followed by breast (16.3%) and brain cancer 
patients (10.2%). By contrast, cancers of the adrenal gland, the 
cartilage, and the penis were only described once.
Immunohistochemical staining of CAIX was predominantly 
performed using the M75 antibody (46.3%) targeting the proteo-
glycan domain of CAIX (31, 32). Other studies used anti-CAIX 
antibodies obtained from different suppliers. A membranous 
expression of CAIX was described in 46.3% of the studies, 
although cytoplasmatic staining or a combination of the two 
was also reported (4.8 and 17.7%, respectively). Nuclear staining 
was only reported in one paper, whereas the rest did not state 
the staining localization. Different quantification methods and 
thresholds have been applied to stratify patients into groups with 
FiGURe 2 | Summary plot of the overall HRs from each endpoint 
analyzed. Symbols represent the HR with 95%CI, and dashed line indicates 
no association between CAIX expression and prognosis.
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low and high tumoral CAIX expression. Taken together, 33.9% of 
the total tumors were classified as expressing high levels of CAIX.
Overall, patients suffering from tumors with high CAIX 
expression had a worse treatment outcome (Figure 2). This asso-
ciation was strong and significant for all endpoints. The negative 
association of CAIX expression with outcome was dominant 
for DFS and weaker for LC. Systematic heterogeneity in the 
present meta-analysis as demonstrated by an asymmetric funnel 
plot (21) for most of the endpoints (Image 1 in Supplementary 
Material) can at least in part be attributed to the considerable 
variation in tumor types and sites across the studies. Therefore, 
in addition, subgroup analysis based on organ site of the tumor 
was performed. The results of the subgroup analysis demonstrate 
a significant prognostic value of CAIX in most of the cancer types 
investigated (see below).
Overall Survival
Effect of pretreatment expression of CAIX on OS could be evalu-
ated in 104 studies. The complete data to estimate the HR could 
not be retrieved from 11 papers and were therefore not included in 
the analysis [Table 1 in Supplementary Material (33–43)]. Overall, 
high CAIX expression was associated with a worse OS (HR = 1.76, 
95%CI 1.58–1.98, p < 0.0001, Figure 3). Subgroup analysis of the 
different organ sites revealed a similar significant association 
between tumoral CAIX expression and OS in 11 organ sites: blad-
der (HR = 1.64, 95%CI = 1.21–2.22), brain (HR = 2.18, 95%CI 
1.60–2.96), breast (HR = 1.90, 95%CI = 1.45–2.50), esophagus 
(HR = 1.97, 95%CI 1.50–2.60), gall bladder (HR = 2.35, 95%CI 
1.33–4.15), gastroenteropancreatic tract (HR  =  2.57, 95%CI 
1.45–4.56), head and neck (HR = 1.66, 95%CI 1.29–2.13), lung 
(HR =  1.57, 95%CI 1.06–2.33), pancreas (HR =  2.37, 95%CI 
1.04–5.43), soft tissue (HR =  2.97, 95%CI 1.65–5.34), and the 
stomach (HR =  1.92, 95%CI 1.39–2.67). The other six organ 
sites show a similar trend with worse OS, albeit not statistically 
significant (Table 1). Similar results were often, but not always, 
observed for different tumor types per organ site (Table 2 in 
Supplementary Material). A hypoxia-associated perinecrotic 
staining pattern was reported in 16 of these studies, whereas a 
diffuse staining pattern was reported in 3 papers. Interestingly, 
both patterns of CAIX expression significantly associated with OS 
(perinecrotic: HR = 1.99, 95%CI 1.60–2.48; diffuse: HR = 1.77, 
95%CI 1.22–2.56). These results suggest that the expression pat-
tern of CAIX does not affect its prognostic value.
Disease-Free Survival
A total of 40 from the selected 147 studies investigated the associa-
tion between CAIX expression and DFS. Five studies could not be 
included in this analysis due to incomplete reporting [Table 1 in 
Supplementary Material (39, 40, 43, 124, 130)]. Based on 35 studies, 
high CAIX expression was statistically significantly associated with a 
decreased DFS (HR = 1.87, 95%CI 1.62–2.16, p < 0.001) (Figure 4). 
Subgroup analysis based on organ site of the tumor showed that high 
CAIX expression was significantly associated with shorter DFS in 
bladder (HR = 2.63, 95%CI 1.56–4.40), breast (HR = 1.74, 95%CI 
1.34–2.27), colorectal (HR =  3.31, 95%CI 1.23–8.89), esophagus 
(HR = 2.70, 95%CI 2.08–3.50), head and neck (HR = 1.98, 95%CI 
1.51–2.61), liver (HR = 1.51, 95%CI 1.26–1.81), lung (HR = 1.87, 
95%CI 1.27–2.74), and soft tissue tumors (HR = 3.41, 95%CI 1.58–
7.30). By contrast, no significant association with DFS was observed 
for tumors in the cervix (HR = 1.12, 95%CI 0.75–1.68), pancreas 
(HR = 2.98, 95%CI 0.56–15.9), penis (HR = 1.35, 95%CI 0.55–3.30), 
stomach (HR = 1.27, 95%CI 0.77–2.10), and vulva (HR = 1.52, 95%CI 
0.79–2.90) (Table 1). A similar trend was observed for all different 
tumor types per organ sites (Table 2 in Supplementary Material).
Locoregional Control
The risk of locoregional relapse associated with CAIX expression 
was evaluated in 25 studies in 6 different organ sites. Figure 5 
shows the overall LC outcome, which indicates that patients with 
high tumoral CAIX expression have a higher risk of locoregional 
recurrences than patients with low expression of CAIX in 
tumors (HR = 1.54, 95%CI 1.22–1.93, p = 0.0002). The negative 
association between high CAIX expression in tumors and worse 
LC remained significant in head and neck (HR =  1.54, 95%CI 
1.12–2.12) and liver tumors (HR  =  1.39, 95%CI 1.09–4.10) 
(Table  1). A similar association was observed in most of the 
tumor types per organ sites (Table 2 in Supplementary Material).
Disease-Specific Survival
Disease-specific survival was reported in 23 studies, of which 
1 study provided incomplete data to estimate the HR [Table 1 
in Supplementary Material (43)]. In the remaining 22 studies, 
patients suffering from tumors with high CAIX expression 
had a significantly shorter DSS (HR =  1.78, 95%CI 1.41–2.25, 
p < 0.0001) (Figure 6). Subgroup analyses by organ site revealed 
significant associations between high CAIX expression and worse 
DSS in tumors of the breast (HR = 1.75, 95%CI 1.28–2.38), cervix 
(HR =  2.19, 95%CI 1.29–3.70), esophagus (HR =  2.78, 95%CI 
1.56–5.00), head and neck (HR = 2.21, 95%CI 1.12–4.36), pan-
creas (HR = 1.49, 95%CI 1.07–2.10), and soft tissue (HR = 1.65, 
95%CI 1.11–2.45) (Table  1). Subgroup analyses of the tumor 
types per organ sites revealed a worse DSS to be associated with 
high CAIX expression in the majority of tumor types (Table 2 in 
Supplementary Material).
Metastasis-Free Survival
Metastasis-free survival was reported in 12 of the 147 
included studies. Based on 11 of these studies, high CAIX 
FiGURe 3 | Forest plot of the papers describing the association between CAiX expression and OS. Horizontal bars represent HR with corresponding 
95%CI. Symbol size represents the assigned weight of the study. The overall HR with 95%CI is visualized with the diamond shape. Dashed line indicates no 
association between CAIX and prognosis. Esop, Stom, esophagus and stomach; GEP, gastroenteropancreatic tract (25–27, 29, 30, 44–129).
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FiGURe 3 | Continued 
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expression was significantly associated with a shorter MFS 
(HR =  1.82, 95%CI 1.33–2.50, p =  0.0002) [Figure 7; Table 
1 in Supplementary Material (166)]. Subgroup analyses of 
the different organ sites of the tumors, independent of tumor 
types, revealed high CAIX expression to be significantly 
associated with a worse MFS in most of the organ sites 
reported, i.e., breast (HR = 1.76, 95%CI 1.13–2.74), cartilage 
(HR =  6.46, 95%CI 2.05–20.0), cervix (HR =  2.37, 95%CI 
1.35–4.10), colorectal (HR  =  5.17, 95%CI 2.07–13.0), and 
vulva (HR =  2.25, 95%CI 1.42–3.60), but not in head and 
neck (HR =  0.77, 95%CI 0.27–2.26) and soft tissue cancers 
(HR =  1.65, 95%CI 0.72–3.80) (Table  1). Interestingly, one 
study reported a significant positive association between high 
CAIX expression and better MFS in squamous cell carcinoma 
of the head and neck (HR = 0.27, 95%CI 0.09–0.80) (Table 2 
in Supplementary Material), which may be attributed to the 
hypoxia-modifying component of the treatment (24).
Progression-Free Survival
Eleven out of 12 studies could be included to estimate the risk of 
disease progression after treatment based on CAIX expression 
in tumors [Table 1 in Supplementary Material (169)]. Similar 
to the other endpoints, PFS was significantly shorter in patients 
with tumors expressing high levels of CAIX (HR = 1.58, 95%CI 
1.27–1.96, p < 0.0001) (Figure 8). Subgroup analyses per organ 
site revealed that the association with PFS only remained statisti-
cally significant in breast (HR = 1.88, 95%CI 1.13–3.10), colo-
rectal (HR = 2.38, 95%CI 1.06–5.56), and head and neck tumors 
(HR = 1.62, 95%CI 1.01–2.59) (Table 1). The subgroup analyses 
of tumor types per organ site showed similar associations between 
TABLe 1 | Results of subgroup meta-analyses of different organ sites reported.
Organ site OS DFS LC DSS MFS PFS
Bladder 1.64 (1.21–2.22) 2.63 (1.56–4.40) 0.88 (0.40–1.90) 0.82 (0.47–1.4) 0.68 (0.21–2.20)
Brain 2.18 (1.60–2.96) 1.44 (0.91–2.27)
Breast 1.90 (1.45–2.50) 1.74 (1.34–2.27) 1.37 (0.95–1.96) 1.75 (1.28–2.38) 1.76 (1.13–2.74) 1.88 (1.13–3.10)
Cartillage 6.46 (2.05–20.0)
Cervix 1.11 (0.91–1.35) 1.12 (0.75–1.68) 1.17 (0.74–1.87) 2.19 (1.29–3.70) 2.37 (1.35–4.10) 1.76 (0.99–3.10)
Colorectal 1.41 (0.67–2.98) 3.31 (1.23–8.89) 3.33 (1.76–6.30) 1.31 (0.18–9.41) 5.17 (2.07–13.0) 2.38 (1.06–5.56)
Esophagus 1.97 (1.50–2.60) 2.70 (2.08–3.50) 2.78 (1.56–5.00)
Esop, Stom 1.53 (1.00–2.30)
Gall Bladder 2.35 (1.33–4.15)
GEP 2.57 (1.45–4.56)
H&N 1.66 (1.29–2.13) 1.98 (1.51–2.61) 1.54 (1.12–2.12) 2.21 (1.12–4.36) 0.77 (0.27–2.26) 1.62 (1.01–2.59)
Liver 1.41 (0.98–2.03) 1.51 (1.26–1.81) 1.39 (1.09–4.10)
Lung 1.57 (1.06–2.33) 1.87 (1.27–2.74) 1.75 (0.59–5.15)
Ovary 1.42 (0.82–2.45) 1.24 (0.67–2.30)
Pancreas 2.37 (1.04–5.43) 2.98 (0.56–15.9) 1.49 (1.07–2.10)
Penis 1.35 (0.55–3.30)
Small Intestine 2.58 (0.21–31.8)
Soft tissue 2.97 (1.65–5.34) 3.41 (1.58–7.30) 1.65 (1.11–2.45) 1.65 (0.72–3.80)
Stomach 1.92 (1.39–2.67) 1.27 (0.77–2.10)
Vulva 1.52 (0.79–2.90) 1.34 (0.67–2.70) 2.25 (1.42–3.60)
The overall HR (with 95%CI) is shown. When HR was available from only one paper, the values were adopted from that single paper. Bold numbers indicate statistical significant 
associations between CAIX expression and prognosis (p < 0.01).
Esop, Stom, esophagus and stomach; GEP, gastroenteropancreatic tract.
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high CAIX expression and a worse PFS (Table 2 in Supplementary 
Material).
High-Quality Papers
This meta-analysis used an adjusted version of the NOS to evalu-
ate the quality of a study. The scores of this quality assessment 
ranged between 1 and 7 stars, i.e., the maximum, awarded per 
study. Approximately half of the studies (52.4%) were considered 
as high-quality studies, i.e., with a number of stars greater or 
equal to the median (5 stars). Meta-analysis of only the high-
quality studies revealed significant prognostic values of CAIX 
expression for OS (HR = 1.81, 95%CI 1.57–2.09, n = 50), DFS 
(HR = 1.81, 95%CI 1.47–2.23, n = 18), DSS (HR = 1.71, 95%CI 
1.16–2.51, n = 10), and PFS (HR = 1.59, 95%CI 1.21–2.07, n = 7). 
For both LC (HR =  1.90, 95%CI 1.58–2.30, n =  14) and MFS 
(HR = 2.47, 95%CI 1.92–3.19, n = 7), the association with CAIX 
expression became even stronger when only high-quality studies 
were included.
DiSCUSSiON
Many clinical studies investigated the prognostic association 
of CAIX expression with treatment outcome. Most of these 
studies, however, include only limited numbers of patients 
and remain inconclusive. This current meta-analysis is 
the first complete overview of all reported clinical studies 
investigating the impact of pretreatment CAIX expression in 
solid tumors on prognosis. Overall, these results clearly show 
that high CAIX expression is an adverse prognostic marker 
in solid tumors, irrespectively of the endpoint evaluated, as 
summarized in Figure 2. A strong association between high 
CAIX expression and poor prognosis was also found in the 
majority of different tumor sites, supporting an important role 
of CAIX in disease progression and treatment resistance in 
many cancer types.
The papers included in the current meta-analysis were all 
published between 2001 and 2015, which is likely attributed to the 
identification of the hypoxic responsive element in the promotor 
region of ca9 in the end of 2000 (170). This study identified a 
direct link between CAIX expression and its hypoxic upregula-
tion through HIF stabilization. This crucial finding encouraged 
research to evaluate CAIX as an endogenous marker of tumor 
hypoxia, a known biological factor of therapy resistance (2–4). 
Nevertheless, because alternative mechanisms can also regulate 
CAIX expression, e.g., via PI3K (171) or the unfolded protein 
response (10, 172), tumoral CAIX expression may not accurately 
identify hypoxic tumors. Apart from the hypoxia-associated 
mechanisms underlying resistance of tumor cells to several treat-
ment modalities, CAIX can directly affect cancer prognosis as its 
main function is to maintain the balance between intracellular 
and extracellular pH, thereby generating an acidic extracellular 
microenvironment (11, 12). This is supported by data demonstrat-
ing that CAIX is involved in promoting tumorigenesis and leads 
to a more aggressive phenotype of tumor cells (173). This can 
partly be explained by the association between CAIX expression 
and the induction of tumor cell migration and invasion, which 
could be caused by the reduction in extracellular pH (174–176). 
In addition, cancer stem cell markers also appear to be enriched 
in the CAIX expressing population of tumor cells (57, 177). The 
important role of CAIX, either directly or indirectly, in cancer 
FiGURe 4 | Forest plot of the papers describing the association between CAiX expression and DFS. Horizontal bars represent HR with corresponding 
95%CI. Symbol size represents the assigned weight of the study. The overall HR with 95%CI is visualized with the diamond shape. Dashed line indicates no 
association between CAIX and prognosis (29, 33, 34, 48, 57, 59, 68, 73, 74, 82, 84, 85, 87, 89, 90, 97, 98, 112, 117, 119, 121, 125, 131–143).
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prognosis is also supported by the results of the current meta-
analysis, which shows that tumors with high CAIX expression 
have higher risk of locoregional failure, disease progression, and 
higher risk to develop metastasis. Other proton exchangers and 
transporters have been shown preclinically and clinically to play 
an important role in the regulation of cellular pH homeostasis 
promoting survival and invasion as well as causing treatment 
resistance (178–180). Therefore, assessment of several major pH 
regulators in tumors prior and/or during therapy may represent 
a more powerful prognostic and predictive biomarker as well as 
important targets for new anti-cancer treatments, which warrants 
further investigations.
A meta-analysis usually overestimates its results because of 
selective reporting and publication bias (21). This meta-analysis 
identified a total of 147 studies reported in 144 papers of which 
15 could not be included in final analysis because the HR could 
not be estimated due to incomplete reporting (33–43, 124, 
130, 166, 169). Non-significant association between CAIX and 
outcome was found in these studies (Table 1 in Supplementary 
Material). Including these 15 papers in the analysis might 
therefore decrease the magnitude of the prognostic values 
of CAIX expression reported here. This overestimation can 
be further increased by publication bias, i.e., when negative 
associations are not published at all and can therefore not be 
identified and included in this meta-analysis. Nevertheless, 
since the prognostic value of CAIX expression was highly 
statistically significant, we believe that the possible effect of 
publication bias on this association is minimal.
FiGURe 5 | Forest plot of the papers describing the association between CAiX expression and LC. Horizontal bars represent HR with corresponding 
95%CI. Symbol size represents the assigned weight of the study. The overall HR with 95%CI is visualized with the diamond shape. Dashed line indicates no 
association between CAIX and prognosis (24–28, 52, 59, 94, 95, 112, 116, 122, 133, 144–155).
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The different staining and scoring methods used in the included 
papers to quantify CAIX expression might be an additional 
source of bias. Visual quantification was used in the majority of 
the reports and could either be based on staining intensity, the 
number of stained cells, or a combination of both. In addition, 
different thresholds have been used to dichotomize patients based 
on their CAIX expression. This discrepancy in methods is one of 
the reasons of significant heterogeneity between studies, which 
therefore requires the use of a random-effect model in the meta-
analysis (181, 182). Additionally, tissue microarrays (TMAs) are 
used in the majority of included papers to visualize and quantify 
CAIX expression, even though TMAs may underestimate the 
actual expression levels of the protein (183). The use of TMAs 
might therefore bias the prognostic value of CAIX when CAIX 
expression levels are dichotomized erroneous. Furthermore, this 
meta-analysis is limited by difficulties in obtaining homogenous 
endpoints and by non-uniform observation times, although most 
of the data are based on reports with a median follow-up of more 
than 1 year.
To identify possible bias in a selected study, an adjusted ver-
sion of the NOS was used, which is a quick and easy method to 
assess the quality of studies that has been commended in the 
Cochrane handbook (21). However, the validity and reproduc-
ibility of the NOS have been questioned because of the subjec-
tive interpretation of certain criteria, which require detailed 
guidelines to obtain a better inter-rater agreement (184–186). 
The test–retest reliability of the NOS is, however, better, which 
allows for a single reviewer to continuously use uniform criteria 
while rating papers (185). When only high-quality papers, i.e., 
those with minimal bias, were included in our analyses, there 
was no significant difference in the results as compared with all 
studies included.
It remains impossible to eliminate every source of bias in 
a meta-analysis. Nevertheless, the high statistical significance 
of the results presented here clearly show that CAIX expres-
sion is associated with worse prognosis in a global patient 
population and in the majority of tumor sites. These find-
ings are similar to the results of the meta-analysis in head 
and neck cancer (14), but different from RCC (13) due to the 
alternative mechanism of CAIX upregulation in RCC (15, 16). 
New treatment options are currently being developed to spe-
cifically inhibit CAIX function (6, 187), of which one is cur-
rently in a Phase I clinical trial (NCT02215850). These types 
of compounds might prove to be beneficial for the specific 
FiGURe 6 | Forest plot of the papers describing the association between CAiX expression and DSS. Horizontal bars represent HR with corresponding 
95%CI. Symbol size represents the assigned weight of the study. The overall HR with 95%CI is visualized with the diamond shape. Dashed line indicates no 
association between CAIX and prognosis (29, 78, 95, 102, 136, 138, 140, 144, 150, 152, 154, 156–165).
FiGURe 7 | Forest plot of the papers describing the association between CAiX expression and MFS. Horizontal bars represent HR with corresponding 
95%CI. Symbol size represents the assigned weight of the study. The overall HR with 95%CI is visualized with the diamond shape. Dashed line indicates no 
association between CAIX and prognosis (24, 27, 34, 52, 95, 102, 140, 34, 150, 165, 167, 168).
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treatment of tumors with high CAIX expression. The results 
of this meta-analysis further support the development of a 
clinical test to determine patient prognosis based on CAIX 
expression, although a standardized protocol remains to be 
developed and validated.
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